Skip to main content
Premium Trial:

Request an Annual Quote

William Franzblau, Randy Berholtz, Byron Hewett


Nanogen has appointed William Franzblau as its vice president of legal affairs. Randy Berholtz, the acting general counsel and secretary, will become senior corporate counsel and senior director of business development. As vice president of legal affairs, Franzblau will be responsible for developing and executing Nanogen’s business plans.

“The goals are to assist the company in the commercialization of the products,” Franzblau said. “I not only bring legal experience but also have business experience, helping put deals together.”

Franzblau comes to Nanogen from Atabok, a digital rights management company for business-to-business communications. From 1993 to 1999, he served as general counsel and chief financial officer of Hemagen Diagnostics. Franzblau received his Masters in Taxation and J.D. degree from Boston University School of Law.


Qiagen of Venlo, the Netherlands, has hired Byron Hewett as senior vice president for sales and marketing and general manager. Hewett will be in charge of the company’s North American sales and marketing operations. These markets represent more than 50 percent of Qiagen’s consolidated net sales, the company said.

Most recently, Hewett was vice president of worldwide marketing for Bayer’s laboratory testing business unit, where he directed global strategic development as well as development and commercialization of new products. Before that he served as head of Bayer’s US laboratory lesting and nucleic acid diagnostics businesses.

The Scan

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.